Mepolizumab, a Humanized Monoclonal Antibody to IL-5, for Severe Eosinophilic Esophagitis in Adults: A Randomized, Placebo-Controlled Double-Blind Trial

Abstract

Background: Eosinophilic esophagitis (EE) is a clinicopathological condition defined by proton pump inhibitor–refractory esophagus-related symptoms in combination with dense esophageal eosinophilia. Interleukin (IL)-5 is the major cytokine responsible for the differentiation, recruitment, and activation of eosinophils. Mepolizumab (Mepo) binds specifically to and inactivates IL-5. This pilot study evaluated the tolerability, efficacy, and pharmacokinetics of Mepo in adults with severe EE unresponsive to or dependent on corticosteroids.